Structure-activity relationship of a novel class of naphthyl amide KATP channel openers

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 10, 2003, Pages 1741-1744

  Turner, Sean C ^a   Carroll, William A ^a   White, Tammie K ^a   Brune, Michael E ^a   Buckner, Steven A ^a   Gopalakrishnan, Murali ^a   Fabiyi, Adebola ^a   Coghlan, Michael J ^a   Scott, Victoria E ^a   Castle, Neil A ^b   Daza, Anthony V ^a   Milicic, Ivan ^a   Sullivan, James P ^a  

^a ABBOTT LABORATORIES   (United States)

^b Icagen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 1 (1,1 DIMETHYLPROPYL) 3 (3 PYRIDYL)GUANIDINE; 4 [3,4 DIOXO 2 (1,2,2 TRIMETHYLPROPYLAMINO) 1 CYCLOBUTENYLAMINO] 3 ETHYLBENZONITRILE; A 151892; AMIDE; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; NAPHTHALENE DERIVATIVE; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER; BLADDER CONTRACTION; BLADDER FUNCTION; BLADDER OBSTRUCTION; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OVERACTIVE BLADDER; RAT; STRUCTURE ACTIVITY RELATION; SWINE;

SUS SCROFA; TRIFLUORO;

EID: 0038363855     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00205-1     Document Type: Article

References (21)

1. Andersson K.-E. Urology. 50:1997;74.
2. Coghlan M.J., Carroll W.A., Gopalakrishnan M. J. Med. Chem. 44:2001;1628.
3. (a) Nurse D.E., Restorick J.M., Mundy A.R. Br. J. Urol. 68:1991;27
4. (b) Restorick J.M., Nurse D.E. Neurourol. Urodyn. 7:1988;207.
5. (a) Chess-Williams R., Martin S.W., Korstanje C., Chapple C.R. Br. J. Urol. 83:1999;1050
6. (b) Zografos P., Li J.H., Kau S.T. Pharmacology. 45:1992;216
7. (c) Martin S.W., Radley S.C., Chess-Williams R., Korstanje C., Chapple C.R. Br. J. Urol. 80:1997;405.
8. Li J.H. Cardiovasc. Drug Rev. 15:1997;220.
9. Brune M.E., Fey T.A., Brioni J.D., Sullivan J.P., Williams M., Carroll W.A., Coghlan M.J., Gopalakrishnan M. J. Pharmacol. Exp. Ther. 303:2002;387.
10. (a) Butera J.A., Antane M.M., Antane S.A., Argentieri T.M., Freeden C., Graceffa R.F., Hirth B.H., Jenkins D., Lennox J.R., Matelan E., Norton N.W., Quagliato D., Sheldon J.H., Spinelli W., Warga D., Wojdan A., Woods M. J. Med. Chem. 43:2000;1187
11. (b) Gilbert A.M., Antane M.M., Argentieri T.M., Butera J.A., Francisco G.D., Freeden C., Gundersen E.G., Graceffa R.F., Herbst D., Hirth B.H., Lennox J.R., McFarlane G., Norton N.W., Quagliato D., Sheldon J.H., Warga D., Wojdan A., Woods M. J. Med. Chem. 43:2000;1203.
12. A preliminary report of this study was given at the XVIIth International Symposium on Medicinal Chemistry, 2002, Barcelona, Spain.
13. (a) Knunyants G., Ch'en R. Izv. Akad. Nauk SSSR, Otd. Khirn. Nauk. 1962;684
14. (b) Gilbert E.E., Jones E.S., Sibilia J.P. J. Org. Chem. 30:1965;1001.
15. Scott, V. E.; Davis-Taber, R.; Silvia, C.; Hoogenboom, L.; Choi, W.; Kroeger, P.; Whiteaker, K.; Gopalakrishnan, M. J. Pharm. Exp. Ther. Submitted for publication.
16. Quast U., Bray K.M., Andres H., Manley P.W., Baumlin Y., Dosogne J. Molecular Pharmacology. 43:1993;474.
17. (a) Buckner S.A., Milicic I., Daza A., Davis-Taber R., Scott V.E., Sullivan J.P., Brioni J.D. Eur. J. Pharmacol. 400:2000;287
18. (b) Buckner S.A., Milicic I., Daza A.V., Coghlan M.J., Gopalakrishnan M. Brit. J. Pharmacology. 135:2002;639.
19. (a) Fabiyi A., Gopalakrishnan M., Brioni J.D., Coghlan M.J., Brune M.E. Brit. J. Urol. 91:2003;284
20. (b) Malmgren A., Sjogren C., Uvelius B., Mattiasson A., Andersson K.E., Andersson P.O. J. Urol. 137:1987;1291.
21. Compounds dissolved in a solution containing equal parts of a hydroxypropyl-beta-cyclodextrin solution (100 g/200 mL) and sterile water, and dosed in a volume of 1 mL/kg, warmed to body temperature before injection, and administered slowly over 2 min.